Remdesivir CAS 1809249-37-3

Remdesivir CAS 1809249-37-3

Identification

CAS Number

1809249-37-3

Name

Remdesivir

Synonyms

remdesivir [INN]
(2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytétrahydro-2-furanyl]méthoxy}(phénoxy)phosphoryl]amino}propanoate de 2-éthylbutyle (non-preferred name) [French] [ACD/IUPAC Name]
2-Ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydro-2-furanyl]methoxy}(phenoxy)phosphoryl]amino}propanoate (non-preferred name) [ACD/IUPAC Name]
2-Ethylbutyl-(2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyan-3,4-dihydroxytetrahydro-2-furanyl]methoxy}(phenoxy)phosphoryl]amino}propanoat (non-preferred name) [German] [ACD/IUPAC Name]
GS-5734 [Wiki]
remdesivir [Spanish] [INN]
remdésivir [French] [INN]
remdesivirum [Latin] [INN]
UNII:3QKI37EEHE
ремдесивир [Russian] [INN]
ريمديسيفير [Arabic] [INN]
瑞德西韦 [Chinese] [INN]
1809249-37-3 [RN]

Molecular Structure

Structure of Remdesivir CAS 1809249 37 3 - Remdesivir CAS 1809249-37-3

SMILES

CCC(CC)COC(=O)[[email protected]](C)N[[email protected]](=O)(OC[[email protected]@H]1[[email protected]]([[email protected]]([[email protected]](O1)(C#N)c2ccc3n2ncnc3N)O)O)Oc4ccccc4

StdInChI

InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1

StdInChIKey

RWWYLEGWBNMMLJ-YSOARWBDSA-N

Molecular Formula

C27H35N6O8P

Molecular Weight

602.576

Properties

Appearance

Powder

Density

1.47±0.1 g/cm3

Acidity coefficient (pKa)

12.00±0.70(Predicted)

Safety Data

WGK Germany

3

Specifications and Other Information of Our Remdesivir CAS 1809249-37-3

Identification Methods

HNMR, HPLC

Purity

98% min

Shelf Life

1 year

Storage

Under room temperature away from light.

Known Application

Remdesivir is a nucleoside analogue and is an RNA-dependent RNA polymerase (RdRp) inhibitor. It can synthesize antivirals by inhibiting viral nucleic acids. Data from in vitro experiments and animal models indicate that Radixivir inhibits RNA-derived RNA polymerase (RdRp), which includes atypical pneumonia (SARS coronavirus), Middle East respiratory syndrome (MERS coronavirus) , Ebol Chemicalbook Coronavirus and many other coronaviruses. In vitro cell experiments showed that the half effective concentration (IC50) of Radixivir to the new coronavirus was 0.77 μmol·L-1. A clinical Chemicalbook bed study for Ebola virus infection is currently in phase II. MERS-infected mice performed much better with this combination therapy, with reduced virus replication and improved lung function. Recent studies have shown that Radixivir has a certain activity in inhibiting the new crown virus.

This product is developed by our R&D company Caming Pharmaceutical Ltd(http://www.caming.com/), and here is the corresponding linkhttp://www.caming.com/remdesivir-cas-1809249-37-3/

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you shortly (Please change screen to horizontal for complete browsing if you are checking Watson on your mobile phone).

Product:























Please prove you are human by selecting the Car.